drugset / Trial / NCT03405597

HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg

NCT03405597

Phase 3 Unknown 97 enrolled Mahidol University
RandomizedParallel-groupOpen-labelTreatment

Summary

Chronic HBV infection is major problem in Asian countries. Years after chronic infection, in some cases serum HBsAg level declines to unmeasurable level. Some of patients develop anti-HBsAb but there is no standard treatment to accelerate HBsAg seroconversion. There is a study to determine efficacy and safety of HBV vaccine in who is Chronic HBV infection and lost their HBsAg without seroconversion to anti-HBsAb.

Timeline

Start
2017-03-30
Primary completion
2018-02-28
Completion
2018-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix-B Vaccine 20 ug Subcutaneous